A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies
Publication type: Journal Article
Publication date: 2018-05-01
scimago Q1
wos Q2
SJR: 1.229
CiteScore: 5.7
Impact factor: 3.4
ISSN: 17410126, 17410134
PubMed ID:
29982719
Biochemistry
Molecular Biology
Biotechnology
Bioengineering
Abstract
A novel dual-cytokine-antibody fusion protein, consisting of an antibody directed against CD38 [a tumor-associated antigen mainly expressed on the surface of multiple myeloma (MM) cells], simultaneously fused to both tumor necrosis factor ligand superfamily member 10 (TRAIL) and interleukin-2 (IL2), was designed, expressed and purified to homogeneity. The novel fusion protein, termed IL2-αCD38-αCD38-scTRAIL, was able to selectively recognize its cognate antigen expressed on the surface of MM and lymphoma cell lines, as evidenced by flow cytometry analysis. Moreover, the targeted version of TRAIL was able to induce cancer cell death in vitro, both with MM cell lines and with fresh isolates from the bone marrow of MM patients. The experiments provide a rationale for possible future applications of IL2-αCD38-αCD38-scTRAIL for the treatment of patients with MM or other CD38-positive malignancies.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
|
|
|
Frontiers in Immunology
2 publications, 13.33%
|
|
|
Journal of Clinical Medicine
1 publication, 6.67%
|
|
|
Cellular and Molecular Life Sciences
1 publication, 6.67%
|
|
|
Scientific Reports
1 publication, 6.67%
|
|
|
Antibodies
1 publication, 6.67%
|
|
|
Journal of Controlled Release
1 publication, 6.67%
|
|
|
Acta Pharmaceutica Sinica B
1 publication, 6.67%
|
|
|
International Journal of Cancer
1 publication, 6.67%
|
|
|
OncoTargets and Therapy
1 publication, 6.67%
|
|
|
Biotechnology Advances
1 publication, 6.67%
|
|
|
Cancer Medicine
1 publication, 6.67%
|
|
|
Russian Chemical Reviews
1 publication, 6.67%
|
|
|
1
2
|
Publishers
|
1
2
3
|
|
|
Elsevier
3 publications, 20%
|
|
|
MDPI
2 publications, 13.33%
|
|
|
Frontiers Media S.A.
2 publications, 13.33%
|
|
|
Springer Nature
2 publications, 13.33%
|
|
|
Cold Spring Harbor Laboratory
2 publications, 13.33%
|
|
|
Wiley
2 publications, 13.33%
|
|
|
Taylor & Francis
1 publication, 6.67%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 6.67%
|
|
|
1
2
3
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
15
Total citations:
15
Citations from 2024:
6
(40%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
De Luca R. et al. A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies // Protein Engineering, Design and Selection. 2018. Vol. 31. No. 5. pp. 173-179.
GOST all authors (up to 50)
Copy
De Luca R., Kachel P., Kropivsek K., Snijder B., Manz M., Neri D. A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies // Protein Engineering, Design and Selection. 2018. Vol. 31. No. 5. pp. 173-179.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1093/protein/gzy015
UR - https://doi.org/10.1093/protein/gzy015
TI - A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies
T2 - Protein Engineering, Design and Selection
AU - De Luca, Roberto
AU - Kachel, Paul
AU - Kropivsek, Klara
AU - Snijder, B.
AU - Manz, MG
AU - Neri, Dario
PY - 2018
DA - 2018/05/01
PB - Oxford University Press
SP - 173-179
IS - 5
VL - 31
PMID - 29982719
SN - 1741-0126
SN - 1741-0134
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2018_De Luca,
author = {Roberto De Luca and Paul Kachel and Klara Kropivsek and B. Snijder and MG Manz and Dario Neri},
title = {A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies},
journal = {Protein Engineering, Design and Selection},
year = {2018},
volume = {31},
publisher = {Oxford University Press},
month = {may},
url = {https://doi.org/10.1093/protein/gzy015},
number = {5},
pages = {173--179},
doi = {10.1093/protein/gzy015}
}
Cite this
MLA
Copy
De Luca, Roberto, et al. “A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies.” Protein Engineering, Design and Selection, vol. 31, no. 5, May. 2018, pp. 173-179. https://doi.org/10.1093/protein/gzy015.